blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Extract from the Register of European Patents

EP About this file: EP2513042

EP2513042 - SOLID DAPOXETINE [Right-click to bookmark this link]
StatusThe application is deemed to be withdrawn
Status updated on  10.07.2015
Database last updated on 17.09.2024
Most recent event   Tooltip10.07.2015Application deemed to be withdrawnpublished on 12.08.2015  [2015/33]
Applicant(s)For all designated states
Symed Labs Limited
8-3-166/6 & 7, II Floor Sree Arcade Erragadda Hyderabad 500 018
Andhra Pradesh / IN
[2012/43]
Inventor(s)01 / MOHAN RAO, Dodda
8-3-166
6&7
II Floor, Sree Arcade
Erragadda
Hyderabad 500 018 Andhrapradesh / IN
02 / KRISHNA REDDY, Pingili
8-3-166
6&7
II Floor, Sree Arcade
Erragadda
Hyderabad 500 018 Andhrapradesh / IN
03 / JITHENDER, Aadepu
8-3-166
6&7
II Floor, Sree Arcade
Erragadda
Hyderabad 500 018 Andhrapradesh / IN
 [2012/43]
Representative(s)Best, Michael, et al
Lederer & Keller
Patentanwälte Partnerschaft mbB
Unsöldstrasse 2
80538 München / DE
[N/P]
Former [2012/43]Best, Michael, et al
Lederer & Keller
Patentanwälte
Unsöldstrasse 2
80538 München / DE
Application number, filing date09851230.413.11.2009
WO2009IN00640
Filing languageEN
Procedural languageEN
PublicationType: A2 Application without search report
No.:WO2011058572
Date:19.05.2011
Language:EN
[2011/20]
Type: A2 Application without search report 
No.:EP2513042
Date:24.10.2012
Language:EN
The application published by WIPO in one of the EPO official languages on 19.05.2011 takes the place of the publication of the European patent application.
[2012/43]
Search report(s)International search report - published on:AT30.08.2012
(Supplementary) European search report - dispatched on:EP29.05.2013
ClassificationIPC:C07C217/48, A61K31/138, C07C213/10
[2014/32]
CPC:
C07C217/48 (EP,US); C07C213/10 (US); C07B2200/07 (EP,US)
Former IPC [2013/26]C07C217/48, A61K31/138
Former IPC [2012/43]C07C217/48
Designated contracting statesAT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   SE,   SI,   SK,   SM,   TR [2012/43]
TitleGerman:DAPOXETIN IN FESTER FORM[2012/43]
English:SOLID DAPOXETINE[2012/43]
French:DAPOXÉTINE SOLIDE[2012/43]
Entry into regional phase04.06.2012National basic fee paid 
04.06.2012Search fee paid 
04.06.2012Designation fee(s) paid 
04.06.2012Examination fee paid 
Examination procedure04.06.2012Examination requested  [2012/43]
06.09.2013Amendment by applicant (claims and/or description)
19.11.2013Despatch of a communication from the examining division (Time limit: M04)
25.03.2014Reply to a communication from the examining division
05.07.2014Observations by third parties
17.09.2014Communication of intention to grant the patent
28.01.2015Application deemed to be withdrawn, date of legal effect  [2015/33]
13.03.2015Despatch of communication that the application is deemed to be withdrawn, reason: fee for grant / fee for printing not paid in time  [2015/33]
Divisional application(s)The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  19.11.2013
Fees paidRenewal fee
04.06.2012Renewal fee patent year 03
29.11.2012Renewal fee patent year 04
28.11.2013Renewal fee patent year 05
Penalty fee
Additional fee for renewal fee
30.11.201406   M06   Not yet paid
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court
See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Documents cited:Search[XP]  - LI L ET AL, "Isolation and structural elucidation of dapoxetine as an adulterant in a health supplement used for sexual performance enhancement", JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, NEW YORK, NY, US, vol. 50, no. 5, doi:10.1016/J.JPBA.2009.06.005, ISSN 0731-7085, (20091205), pages 724 - 728, (20090612), XP026640004 [XP] 1,13 * the whole document *

DOI:   http://dx.doi.org/10.1016/j.jpba.2009.06.005
 [X]  - ALEXANDRE MATHIEU AND WOLFGANG ALBRECHT ET AL, "Improved resolution of (S)-dapoxetine and solid-state characterization of its hydrochloride salt", RESEARCH DISCLOSURE, MASON PUBLICATIONS, HAMPSHIRE, GB, (20081101), vol. 535, no. 12, ISSN 0374-4353, page 928, XP007138541 [X] 7,12 * paragraphs [02.8] , [0003] *
 [A]  - TORRE O ET AL, "Lipase-catalyzed resolution of chiral 1,3-amino alcohols: application in the asymmetric synthesis of (S)-dapoxetine", TETRAHEDRON ASYMMETRY, PERGAMON PRESS LTD, OXFORD, GB, vol. 17, no. 5, doi:10.1016/J.TETASY.2006.02.022, ISSN 0957-4166, (20060306), pages 860 - 866, (20060306), XP024962194 [A] 1-13 * paragraph [4.15] *

DOI:   http://dx.doi.org/10.1016/j.tetasy.2006.02.022
International search[A]WO2008035358  (CADILA HEALTHCARE LTD [IN], et al);
 [A]CN101367739  (TAIZHOU VOCATIONAL & TECHNICAL [CN])
 [A]  - SIDDIQUI, SHAFT A. ET AL., "Enantioselective synthesis of (S)-dapoxetine", TETRAHEDRON: ASYMMETRY, (2007), vol. 18, no. 17, doi:doi:10.1016/j.tetasy.2007.07.028, pages 2099 - 2103, XP022278206

DOI:   http://dx.doi.org/10.1016/j.tetasy.2007.07.028
ExaminationWO2008035358
by applicantEP0288188
 US5292962
 WO2008035358
    - TETRAHYDRON: ASYMMETRY, (2006), vol. 17, pages 860 - 866
    - TETRAHYDRON: ASYMMETRY, (2007), vol. 18, pages 2099 - 2103
    - LIN LI ET AL., JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, (2009), vol. 50, no. 5, pages 724 - 728
    - MATHIEU ET AL., Research Disclosure, MASON PUBLICATIONS, (2008), vol. 535, page 928
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.